Islet transplant breakthrough
Sana Biotechnology reported 14-month follow-up data from a first-in-human islet cell transplant trial showing sustained survival and function of transplanted insulin-producing cells without immunosuppression—potentially freeing patients from daily insulin therapy []. Morgan Stanley reiterated a positive outlook on Sana’s stock, calling the UP421 and SC451 hypoimmune-modified islet programs key innovation platforms in diabetes care [].
The investigator‑sponsored trial is being conducted at Uppsala University Hospital financialcontent.com and treated a single low‑dose patient, a cohort the coverage says was not intended to measure efficacy investing.com. Fasting and MMTT‑stimulated C‑peptide at Month 14 were reported as comparable to the first six months and higher than months 9 and 12, with the patient recording tighter glycemic control between months 12 and 14, according to the company release and conference coverage financialcontent.com. Sana said it expects to file an IND for SC451 and initiate a Phase 1 trial as early as this year, describing SC451 as a HIP‑modified, stem‑cell‑derived, one‑time therapy, and the full 14‑month dataset was slated for presentation at the ATTD conference this week financialcontent.com. Morgan Stanley reiterated an Overweight rating with a $12 price target and called the durability of immune evasion a “platform‑level de‑risking” event, naming the SC451 IND/Phase‑1 start as the next catalyst; coverage also noted Sana trading near $3.28 with a market cap of about $875M and roughly $138M in cash at year‑end 2025. investing.com
